As of today (2022-05-23), Guardant Health's share price is USD36.77.
Guardant Health's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2022 was USD-2.18. Hence, Guardant Health's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Guardant Health's Price-to-Operating-Cash-Flow or its related term are showing as below:
Guardant Health's Cash Flow from Operations per share for the
three
months ended in Mar. 2022 was USD-0.28.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2022 was USD-2.18.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 4.60% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -17.10% per year.
During the past 6 years, Guardant Health's highest 3-Year average Operating Cash Flow per Share Growth Rate was 4.60% per year. The lowest was -1.40% per year. And the median was -0.10% per year.
Guardant Health Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Guardant Health's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Guardant Health Annual Data
|
|
Trend |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
| Price-to-Operating-Cash-Flow |
|
|
- |
- |
- |
- |
- |
|
Guardant Health Quarterly Data
|
|
Dec16 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
| Price-to-Operating-Cash-Flow |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison
For the Diagnostics & Research subindustry, Guardant Health's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health Price-to-Operating-Cash-Flow Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Guardant Health's Price-to-Operating-Cash-Flow falls into.
Guardant Health Price-to-Operating-Cash-Flow Calculation
Guardant Health's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 36.77 | / | -2.181 |
| = | |
Guardant Health's Share Price of today is USD36.77.
Guardant Health's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was USD-2.18.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Guardant Health Business Description
Traded in Other Exchanges
Address
505 Penobscot Drive, Redwood City, CA, USA, 94063
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
Executives
| Talasaz Amirali |
director, officer: Chairman, President and COO |
18 ISABELLA AVENUE ATHERTON CA 94027 |
| Kaul Samir |
director |
C/O KHOSLA VENTURES 3000 SAND HILL ROAD, BLDG. 3, SUITE 170 MENLO PARK CA 94025 |
| Meresman Stanley J |
director |
2071 HUNTINGTON LANE LOS ALTOS CA 94024 |
| Svf Bluebird (cayman) Ltd |
10 percent owner |
C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
| Svf Enterprise (cayman) Ltd |
10 percent owner |
C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
| Sb Investment Advisers (uk) Ltd |
10 percent owner |
69 GROSVENOR STREET LONDON X0 W1K 3JP |
| Softbank Vision Fund (aiv M1) L.p. |
10 percent owner |
251 LITTLE FALLS DRIVE WILMINGTON DE 19808 |
| Svf Endurance (cayman) Ltd |
10 percent owner |
C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
| Clark Ian T |
director |
SOLAZYME, INC. 225 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080 |
| Eltoukhy Helmy |
director, officer: Chief Executive Officer |
2 BARRY LANE ATHERTON CA 94027 |
| Bertocci Derek A |
officer: Chief Financial Officer |
3070 ORCHARD DRIVE SAN JOSE CA 95134 |
| Saia John G. |
officer: See Remarks |
C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY CA 94063 |
| Gadde Vijaya |
director |
C/O TWITTER INC 1355 MARKET STREET SUITE 900 SAN FRANCISCO CA 94103 |
| Jallal Bahija |
director |
120 MONUMENT CIRCLE INDIANAPOLIS IN 46204 |
| Nishar Dipchand |
director |
C/O LINKEDIN CORPORATION 2029 STIERLIN COURT MOUNTAIN VIEW CA 94043 |
Guardant Health Headlines
By tipranks.com 2022-04-05
By Seekingalpha 2021-11-04
By Seekingalpha 2022-02-23
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
2.02(5.81%) Volume: 1,625,702 8:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:GH has been successfully added to your 